Design Therapeutics, Inc. DSGN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Design Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s return on equity?
- Design Therapeutics, Inc. (DSGN) reported return on equity of -31.3% in Q1 2026.
- How has Design Therapeutics, Inc.'s return on equity changed year-over-year?
- Design Therapeutics, Inc.'s return on equity decreased by 38.4% year-over-year, from -22.6% to -31.3%.
- What is the long-term trend for Design Therapeutics, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Design Therapeutics, Inc.'s return on equity has grown at a 19.8% compound annual growth rate (CAGR), from -17.8% to -30.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.